Invasive Implanted Hemodynamic Monitoring in Patients With Complex Congenital Heart Disease: State-of-the-Art Review

• Published in: The American journal of cardiology 2024-07, Vol.223, p.123-131
• Main Authors: Marshall V, William H., Wright, Lydia K., Lampert, Brent C., Salavitabar, Arash, Daniels, Curt J., Rajpal, Saurabh
• Format: Article
• Language: English
• Subjects: Blood circulation; Cardiac catheterization; Cardiac Catheterization - methods; CardioMEMS; Cardiovascular disease; Cardiovascular diseases; Case reports; Congenital diseases; Congenital heart disease; Congestive heart failure; Ejection fraction; FDA approval; Fontan; Heart Defects, Congenital - physiopathology; Heart Defects, Congenital - surgery; Heart Defects, Congenital - therapy; Heart diseases; Heart failure; Heart Failure - physiopathology; Heart Failure - therapy; Heart transplantation; Hemodynamic Monitoring - methods; Hemodynamics; Hemodynamics - physiology; Hospitalization; Humans; Hypertension; Implanted hemodynamic monitoring; Intubation; Life span; Liver diseases; Monitoring; Mortality; Patients; Pediatrics; Peptides; Population studies; Pulmonary arteries; Pulmonary hypertension; State-of-the-art reviews; Telemedicine; Titration; Transplants & implants; Ventricular assist devices
• ISSN: 0002-9149; 1879-1913; 1879-1913
• DOI: 10.1016/j.amjcard.2024.05.010

As the number of patients with congenital heart disease (CHD) continues to increase, the burden of heart failure (HF) in this population requires innovative strategies to individualize management. Given the success of implanted invasive hemodynamic monitoring (IHM) with the CardioMEMSTM HF system in adults with acquired HF, this is often suggested for use in patients with CHD, though published data are limited to case reports and case series. Therefore, this review summarizes the available published reports on the use of IHM in patients with complex CHD, describes novel applications, and highlights future directions for study. In patients with CHD, IHM has been used across the lifespan, from age 3 years to adulthood, with minimal device-related complications reported. IHM uses include (1) prevention of HF hospitalizations; (2) reassessment of hemodynamics after titration of medical therapy without repeated cardiac catheterization; (3) serial monitoring of at-risk patients for pulmonary hypertension to optimize timing of heart transplant referral; (4) and hemodynamic assessment with exercise (5) or after ventricular assist device placement. IHM has the potential to reduce the number of cardiac catheterizations in anatomically complex patients and, in patients with Fontan circulation, IHM pressures may have prognostic implications. In conclusion, though further studies are needed, as patients with CHD age and HF is more prevalent, this tool may assist CHD physicians in caring for this complex patient population. [Display omitted]